CI

At a glance

ClinicalIndex Comparison Record
Phase 3Active· 310 enrolled
Drug / intervention
Acalabrutinib (ACP-196) +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02970318
NCT02970318Phase 3Active
CompareCT.gov

A Randomized, Multicenter, Open-Label, Phase 3 Study of Acalabrutinib (ACP-196) Versus Investigator's Choice of Either Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Subjects With R/R Chronic Lymphocytic Leukemia

Acerta Pharma BV·interventional·Posted Nov 22, 2016·Updated May 11, 2026

In Brief

A Phase 3 clinical trial evaluating Acalabrutinib (ACP-196), Rituximab, and 2 other interventions for Chronic Lymphocytic Leukemia. Active but no longer recruiting, targeting 310 participants across 157 sites in 25 countries.

Detailed Summary

This study is designed to evaluate the efficacy of acalabrutinib compared with rituximab in combination with idelalisib or bendamustine in previously treated subjects with chronic lymphocytic leukemia (CLL).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Lymphocytic Leukemia
CountriesAustralia, Austria, Belgium, Bulgaria, Canada, Croatia, Czechia, France, Germany, Hong Kong, Hungary, Israel, Italy, New Zealand, Poland, Russia, Singapore, Slovakia, South Korea, Spain, Sweden, Taiwan, Ukraine, United Kingdom, United States
Collaborators--

Timeline

Phase 3Active
201720182019202020212022202320242025202620272028
First PostedNov 22, 2016
Enrollment StartFeb 2, 2017
Primary CompletionSep 3, 2021
Study CompletionOct 1, 2027
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 9.6 years ago

Interventions

Acalabrutinib (ACP-196)drug

Acalabrutinib monotherapy

Rituximabdrug

Rituximab in combination with idelalisib or bendamustine

Idelalisibdrug

Idelalisib in combination with rituximab

Bendamustinedrug

Bendamustine in combination with rituximab